A non-myeloablative regimen with minimal non relapse mortality for allografting patients with Hodgkin's disease

被引：0
|
作者：
Kottaridis, P
Milligan, D
Chopra, R
Craddock, C
Mahendra, P
Hunter, A
Marsh, J
Chakraverty, R
Mills, A
Kyriakou, C
McKeag, N
Hale, G
Waldmann, H
Linch, D
Goldstone, A
Mackinnon, S
机构：
来源：
BONE MARROW TRANSPLANTATION | 2001年 / 27卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease
    Carella, AM
    Beltrami, G
    Carella, M
    Corsetti, MT
    Scalzulli, RP
    Greco, M
    HAEMATOLOGICA, 2001, 86 (11) : 1121 - 1123
  • [2] Stem cell allografting using a non-myeloablative regimen.
    Tan, P
    Tee, GY
    BLOOD, 1996, 88 (10) : 449 - 449
  • [3] Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma
    Bruno, B
    Ladetto, M
    Mordini, N
    Astolfi, M
    Rotta, M
    Cimolin, L
    Compagno, M
    Veneziano, L
    Aitoro, G
    Gallamini, A
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S123 - S124
  • [4] Non-myeloablative allogeneic transplantation in patients with resistant/refractory Hodgkin's disease
    Pastano, R.
    Gigli, F.
    Rabascio, C.
    Calabrese, L.
    Martinelli, G.
    Peccatori, F.
    BONE MARROW TRANSPLANTATION, 2008, 41 : S250 - S251
  • [5] Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma
    Bruno, Benedetto
    Ferrero, Simone
    Drandi, Daniela
    Festuccia, Moreno
    Patriarca, Francesca
    Mordini, Nicola
    Cena, Silvia
    Barbero, Daniela
    Monitillo, Luigia
    Ferrando, Federica
    Brunello, Lucia
    Fanin, Renato
    Ghione, Paola
    Omede, Paola
    Giaccone, Luisa
    Palumbo, Antonio
    Passera, Roberto
    Boccadoro, Mario
    Ladetto, Marco
    BLOOD, 2014, 124 (21)
  • [6] Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
    Ladetto, M.
    Ferrero, S.
    Drandi, D.
    Festuccia, M.
    Patriarca, F.
    Mordini, N.
    Cena, S.
    Benedetto, R.
    Guarona, G.
    Ferrando, F.
    Brunello, L.
    Ghione, P.
    Boccasavia, V.
    Fanin, R.
    Omede, P.
    Giaccone, L.
    Palumbo, A.
    Passera, R.
    Boccadoro, M.
    Bruno, B.
    LEUKEMIA, 2016, 30 (05) : 1211 - 1214
  • [7] Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Hodgkin's Disease
    Hovgaard, Doris
    Sengelov, Henrik
    Vindelov, Lars
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S197 - S197
  • [8] Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect.
    Kottaridis, PD
    Milligan, DW
    Chopra, R
    Craddock, C
    Kyriacou, C
    Peggs, K
    Cakrabati, S
    Geary, J
    Thuraisundaram, D
    Mahendra, P
    Chakraverty, R
    Hunter, A
    Pettengell, R
    Hale, G
    Waldmann, H
    Linch, DC
    Goldstone, AH
    Mackinnon, S
    BLOOD, 2001, 98 (11) : 416A - 416A
  • [9] Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
    M Ladetto
    S Ferrero
    D Drandi
    M Festuccia
    F Patriarca
    N Mordini
    S Cena
    R Benedetto
    G Guarona
    F Ferrando
    L Brunello
    P Ghione
    V Boccasavia
    R Fanin
    P Omedè
    L Giaccone
    A Palumbo
    R Passera
    M Boccadoro
    B Bruno
    Leukemia, 2016, 30 : 1211 - 1214
  • [10] Allogeneic stem cell transplantation after non-myeloablative preparative regimen in primary refractory Hodgkin's Disease (HD)
    Lentini, G
    Willenbacher, W
    Günzelmann, S
    Roemer, E
    Basara, N
    Fauser, AA
    Kiehl, MG
    BONE MARROW TRANSPLANTATION, 2001, 27 : S290 - S290
12345